Cargando…
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination
Recently, Liau et al. reported the results of Phase 3 clinical trial testing DCVax-L vaccines on patients with glioblastoma. Despite the promising and significant results obtained, the study design and the long-lasting period of recruitment of this work deserve some reflection.
Autores principales: | Pasqualetti, Francesco, Zanotti, Sofia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491746/ https://www.ncbi.nlm.nih.gov/pubmed/36792723 http://dx.doi.org/10.1038/s41416-023-02194-1 |
Ejemplares similares
-
Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
por: Parney, Ian F, et al.
Publicado: (2020) -
The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
por: Pellegatta, Serena, et al.
Publicado: (2013) -
Autologous tumor lysate-loaded dendritic cell vaccination combined with Sunitinib for metastatic renal cell carcinoma
por: Kakimi, Kazuhiro, et al.
Publicado: (2014) -
Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012) -
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
por: Liau, Linda M., et al.
Publicado: (2022)